Navigation Links
Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug
Date:12/9/2010

EMERYVILLE, Calif., Dec. 9, 2010 /PRNewswire/ -- Angelica Therapeutics, Inc., a privately held drug development company focused on the development and commercialization of therapeutics incorporating novel nonimmunogenic fusion toxins, announced that it has received a $244,479 grant under the IRS Qualified Therapeutic Discovery Project Program. The grant is to advance the development of Angelica's lead drug candidate, Angeloxin, a fusion toxin consisting of deimmunized Diphtheria toxin (DT) fused to Interleukin-2 (IL2).  

The Qualified Therapeutic Discovery Project Program was part of the healthcare reform legislation enacted in March of this year and established a one-time pool of $1 billion for grants to small biotech companies developing novel therapeutics which show potential to, among other things, result in new therapies that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions or significantly advance the goal of curing cancer.  

Angelica has collaborated with Antitope, Ltd. (Cambridge, UK) to remove the T cell epitopes from Diphtheria toxin while retaining its cytotoxic potency.  Angeloxin, currently in preclinical development, is the most advanced drug candidate derived from Angelica's technology platform.  It promises to be an advance over Ontak®, currently marketed for the treatment of cutaneous T cell lymphoma and with reports of efficacy in other cancers as well, including peripheral T cell lymphoma and melanoma.

Geoff Davis, CEO of Angelica, said, "We are very pleased to see Angeloxin and the underlying technology platform recognized by this award.  We anticipate that our technology will constitute a significant advance in enabling repeated administration of highly potent and targeted drugs, even to immunocompetent patients, primarily for the treatment of cancer."

About Angelica Therapeutics, Inc. (www.angelicatherapeutics.com):  Angelica is a privately held biotechnology company focused on the development of "best in class" fusion toxins as therapeutics.   Angelica was founded in 2006 and has been funded solely by the founders and private investors.  The founders are Geoff Davis, Ph.D. (previously Chief Scientific Officer of Abgenix, Inc.), Thomas Tedder, Ph.D (Professor of Immunology, Duke University), and John Klacking, Ph.D. (a private investor).


'/>"/>
SOURCE Angelica Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
2. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
3. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
6. Halozyme Therapeutics Realigns Management
7. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
8. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
9. Nile Therapeutics Reports 2010 Third Quarter Financial Results
10. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. ImmunGenes Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 ... Manufacturing Organization (CDMO), held a special event to introduce ... in Lexington, Kentucky . The inaugural ... Piramal Group Chairman Ajay Piramal, and Piramal Pharma ... ...
(Date:3/22/2017)... FinancialBuzz.com News Commentary  ... According to a report by the New ... billion in 2016, and is projected to grow at a compound ... billion by 2025. The medical cannabis market is projected to grow ... 2016, to an estimated $13.3 billion in 2025. These projections do ...
(Date:3/22/2017)... ROCKLAND, Mass. , March 22, 2017 EMD ... Germany , in the U.S. and Canada ... be presented during the poster presentation session at the 65 ... Indian Wells, California on March 24 ... on analyses of a real-world database collected from July 2009 ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the ... in need of skilled pediatric dentistry in Rock Hill, SC, without a ... routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo Agency, a comprehensive ... New York metropolitan region, is embarking on a cooperative charity drive with Family ... present, more than two and a half million children in the United States ...
(Date:3/22/2017)... ... 2017 , ... Schneider Insurance and Financial, a southern Montana firm providing asset ... region, is launching a charity event aimed at raising local support for Zoo Montana. ... State, and is home to a broad variety of animals from all over the ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Senior Citizens ... and prevent a default on the federal debt — including the debt held by ... growing concern, ” said TSCL in a letter to House and Senate budget leaders. ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Sharon Kleyne ... created more than two decades ago to research evaporation of earth’s and the body’s ... promotes better health. Also the host of the nationally syndicated radio program, The Sharon ...
Breaking Medicine News(10 mins):